Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: No time to lose

Current HIV/AIDS Reports

Volumn 6, Issue 2, 2009, Pages 63-67

  Grant, Philip ^a   Zolopa, Andrew ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANAMNESIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION; LUNG TUBERCULOSIS; MEDICAL INFORMATION; MORBIDITY; MORTALITY; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW;

ACUTE DISEASE; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HOSPITALIZATION; HUMANS;

EID: 65349165876     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-009-0010-3     Document Type: Review

References (38)

1. A. Mocroft S. Vella T.L. Benfield 1998 Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group Lancet 352 1725 1730 (Pubitemid 28534954)
2. F.J.J. Palella K.M. Delaney A.C. Moorman 1998 Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 338 853 860
3. K. Buchacz R.K. Baker A.C. Moorman 2008 Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005 AIDS 22 1345 1354
4. Recommendations of the National Institutes of Health, the Centers for Disease Control and Prevention, and the HIV Medicine Association of the Infectious Diseases Society of America: Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. June 18, 2008. Available at http://aidsinfo.nih.gov/content-files/Adult-OI.pdf . Accessed November 18, 2008.
5. B.G. Gazzard 2008 British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 HIV Med 9 563 608
6. G.L. Dean S.G. Edwards N.J. Ives 2002 Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy AIDS 16 75 83 (Pubitemid 34062184)
7. S.A. Shelburne F. Visnegarwala J. Darcourt 2005 Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy AIDS 19 399 406 (Pubitemid 40446186)
8. Zolopa A, Anderson J, Komarow L, et al.: Immediate vs. deferred ART in the setting of an acute AIDS-related opportunistic infection: final results of a randomized strategy trial, ACTG 5164. Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3-6, 2008.
9. G. Breton X. Duval C. Estellat 2004 Determinants of immune reconstitution inflammatory syndrome in HIV type-1 infected patients with tuberculosis after initiation of antiretroviral therapy Clin Infect Dis 39 1709 1712 (Pubitemid 39578550)
10. I. Ratnam C. Chiu N.B. Kandala P.J. Easterbrook 2006 Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort Clin Infect Dis 42 418 427 (Pubitemid 43122323)
11. D.M. Murdoch W. Venter C. Feldman A. Van Rie 2008 Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study AIDS 22 601 610
12. W.B. Park P.G. Choe J.H. Jo 2006 Immune reconstitution inflammatory syndrome in the first year after HAART: influence on long-term clinical outcome AIDS 20 2390 2392
13. Centre for the AIDS Programme of Research in South Africa: Press Release-Important New Research Findings on Treatment of TB-HIV Co-Infection. Available at http://www.caprisa.org . Accessed November 12, 2008.
14. ClinicalTrials.Gov. Available at http://clinicaltrials. gov/ct2/results?term=tuberculosis+AND+HIV . Accessed December 2, 2008.
15. A. Morris R.M. Wachter J. Luce 2003 Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia AIDS 17 73 80 (Pubitemid 36106300)
16. G.P. Bisson R. Nthobatsong R. Thakur 2008 The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswanna J Acquir Immune Defic Syndr 49 227 229
17. M. May J.A. Sterne C. Sabin 2007 Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies AIDS 21 1185 1197 (Pubitemid 46763289)
18. Strategies for Management of Antiretroviral Therapy 2006 CD4+ count-guided interruption of antiretroviral treatment N Engl J Med 355 2283 2296
19. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf . Accessed November 18, 2008.
20. S.M. Hammer J.J. Eron Jr P. Reiss 2008 Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel JAMA 300 555 570
21. E. Giardi S. Sabin A. Monforte 2007 Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing J Acquir Immune Defic Syndr 46 S3 S8 (Pubitemid 47312320)
22. C.A. Sabin C.J. Smith H. Gumley 2004 Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy AIDS 18 2145 2151 (Pubitemid 39463679)
23. T.R. Chadborn K. Baster V.C. Delpech 2005 No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002) AIDS 19 513 520 (Pubitemid 40515855)
24. R. Murri A. Ammassari M. Trotta 2004 Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance J Gen Intern Med 19 1104 1110 (Pubitemid 39552580)
25. A. Ammassari M.P. Trotta R. Murri 2002 Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature J Acquir Immune Defic Syndr 31 S123 S127 (Pubitemid 35453571)
26. A.A. Howard J.H. Arnsten Y. Lo 2002 A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women AIDS 16 2175 2182 (Pubitemid 35387272)
27. E.M. Gardner S. Sharma G. Peng 2008 Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance AIDS 22 75 82 (Pubitemid 350294880)
28. National HIV/AIDS Clinicians' Consultation Center: Dosage form modifications and renal/hepatic dosing of antiretrovirals. Available at http://www.nccc.ucsf. edu/Clinical-Resources/Pharmacy/PDFs/4-07 HIV Dosage Table.pdf . Accessed November 18, 2008.
29. L. Huang A. Quartin D. Jones D.V. Havlir 2006 Intensive care of patients with HIV infection N Engl J Med 355 173 181 (Pubitemid 44050399)
30. M.M. Kitahata T.D. Koepsell R.A. Deyo 1996 Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival N Engl J Med 334 701 706 (Pubitemid 26079805)
31. C.L. Bennett J.B. Garfinkle S. Greenfield 1989 The relation between hospital experience and in-hospital mortality for patients with AIDS-related PCP JAMA 261 2975 2979 (Pubitemid 19126751)
32. P.E. Sax R. Islam R.P. Walensky 2005 Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis Clin Infect Dis 41 1316 1323 (Pubitemid 41532676)
33. H.S. Weinstock I. Zaidi W. Heneine 2004 The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities J Infect Dis 189 2174 2180 (Pubitemid 38757188)
34. R.M. Novak L. Chen R.D. MacArthur 2005 Prevalence of antiretroviral drug resistance mutations in chronically HIVinfected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy Clin Infect Dis 40 468 474 (Pubitemid 40216518)
35. A.M. Wensing D.A. van de Vijver G. Angarano 2005 Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management J Infect Dis 192 958 966 (Pubitemid 41266791)
36. Wheeler W, Mahle K, Bodnar U, et al.: Antiretroviral drug-resistance mutations and subtypes in drug-naïve persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25-28, 2007.
37. J.E. Gallant E. DeJesus J.R. Arribas 2006 Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV N Engl J Med 354 251 260 (Pubitemid 43113030)
38. H.J. Ribaudo D.R. Kuritzkes C.M. Lalama 2008 Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts J Infect Dis 197 1006 1010